Jounce Therapeutics, Inc. (JNCE) Rating Increased to Hold at Zacks Investment Research
Jounce Therapeutics, Inc. (NASDAQ:JNCE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. “
Several other brokerages also recently commented on JNCE. Robert W. Baird restated a “buy” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a research report on Friday, November 10th. J P Morgan Chase & Co set a $28.00 price objective on shares of Jounce Therapeutics and gave the company a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $23.67.
Shares of Jounce Therapeutics (NASDAQ JNCE) opened at $14.28 on Wednesday. Jounce Therapeutics has a 1 year low of $11.05 and a 1 year high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The company had revenue of $18.10 million during the quarter, compared to the consensus estimate of $20.00 million. The firm’s revenue was up 7.1% on a year-over-year basis. sell-side analysts expect that Jounce Therapeutics will post -0.77 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Jounce Therapeutics, Inc. (JNCE) Rating Increased to Hold at Zacks Investment Research” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/jounce-therapeutics-inc-jnce-rating-increased-to-hold-at-zacks-investment-research/1708725.html.
Large investors have recently made changes to their positions in the company. Macquarie Group Ltd. acquired a new position in shares of Jounce Therapeutics during the third quarter worth $124,000. American International Group Inc. increased its holdings in shares of Jounce Therapeutics by 132.2% during the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock worth $149,000 after buying an additional 5,442 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Jounce Therapeutics in the first quarter worth $212,000. TIAA CREF Investment Management LLC bought a new stake in shares of Jounce Therapeutics in the first quarter worth $229,000. Finally, Teachers Advisors LLC grew its stake in shares of Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after purchasing an additional 2,347 shares during the last quarter. Institutional investors own 44.47% of the company’s stock.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.